Prophylaxis with erythropoietin versus placebo reduces acute kidney injury and neutrophil gelatinase-associated lipocalin in patients undergoing cardiac surgery: A randomized, double-blind controlled trial

BMC Nephrology

Volumn 14, Issue 1, 2013, Pages

  Tasanarong, Adis ^a   Duangchana, Soodkate ^a   Sumransurp, Sangduen ^a   Homvises, Boonlawat ^a   Satdhabudha, Opas ^a  

^a THAMMASAT UNIVERSITY   (Thailand)

Author keywords

Acute kidney injury; Cardiac surgery; Erythropoietin; Neutrophil Gelatinase Associated Lipocalin (NGAL)

Indexed keywords

CREATININE; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; RECOMBINANT ERYTHROPOIETIN; SODIUM CHLORIDE; ACUTE PHASE PROTEIN; BIOLOGICAL MARKER; ERYTHROPOIETIN; LCN2 PROTEIN, HUMAN; LIPOCALIN; ONCOPROTEIN;

ACUTE KIDNEY FAILURE; ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL PROTOCOL; CORONARY ARTERY BYPASS GRAFT; CREATININE BLOOD LEVEL; FEMALE; GLOMERULUS FILTRATION RATE; HEART SURGERY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; URINALYSIS; ACUTE KIDNEY INJURY; AGED; COMPARATIVE STUDY; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PLACEBO EFFECT; PREOPERATIVE CARE; PROCEDURES; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TRENDS; URINE;

ACUTE KIDNEY INJURY; ACUTE-PHASE PROTEINS; ADULT; AGED; BIOLOGICAL MARKERS; CARDIAC SURGICAL PROCEDURES; DOUBLE-BLIND METHOD; ERYTHROPOIETIN; FEMALE; HUMANS; LIPOCALINS; MALE; MIDDLE AGED; PLACEBO EFFECT; PREOPERATIVE CARE; PROSPECTIVE STUDIES; PROTO-ONCOGENE PROTEINS;

EID: 84879832920     PISSN: None     EISSN: 14712369     Source Type: Journal    
DOI: 10.1186/1471-2369-14-136     Document Type: Article

References (50)

1. Acute renal failure in critically ill patients: a multinational, multicenter study. Uchino S, Kellum JA, Bellomo R, Doig GS, Morimatsu H, Morgera S, Schetz M, Tan I, Bouman C, Macedo E, et al. JAMA 2005 294 7 813 818 10.1001/jama.294.7.813 16106006 (Pubitemid 41175724)
2. Renal dysfunction after myocardial revascularization: risk factors, adverse outcomes, and hospital resource utilization. The Multicenter Study of Perioperative Ischemia Research Group. Mangano CM, Diamondstone LS, Ramsay JG, Aggarwal A, Herskowitz A, Mangano DT, Ann Intern Med 1998 128 3 194 203 10.7326/0003-4819-128-3-199802010-00005 9454527 (Pubitemid 28078200)
3. Predictors of ARF after cardiac surgical procedures. Tuttle KR, Worrall NK, Dahlstrom LR, Nandagopal R, Kausz AT, Davis CL, Am J Kidney Dis 2003 41 1 76 83 10.1053/ajkd.2003.50025 12500223 (Pubitemid 36043353)
4. Acute renal failure following cardiac surgery. Conlon PJ, Stafford-Smith M, White WD, Newman MF, King S, Winn MP, Landolfo K, Nephrol Dial Transplant 1999 14 5 1158 1162 10.1093/ndt/14.5.1158 10344355 (Pubitemid 29209301)
5. The Society of Thoracic Surgeons: 30-day operative mortality and morbidity risk models. Shroyer AL, Coombs LP, Peterson ED, Eiken MC, DeLong ER, Chen A, Ferguson TB Jr, Grover FL, Edwards FH, Ann Thorac Surg 2003 75 6 1856 1864 discussion 1864-1855 10.1016/S0003-4975(03)00179-6 12822628 (Pubitemid 36677229)
6. Minimal changes of serum creatinine predict prognosis in patients after cardiothoracic surgery: a prospective cohort study. Lassnigg A, Schmidlin D, Mouhieddine M, Bachmann LM, Druml W, Bauer P, Hiesmayr M, J Am Soc Nephrol 2004 15 6 1597 1605 10.1097/01.ASN.0000130340.93930.DD 15153571 (Pubitemid 38679685)
7. Immediate postoperative renal function deterioration in cardiac surgical patients predicts in-hospital mortality and long-term survival. Loef BG, Epema AH, Smilde TD, Henning RH, Ebels T, Navis G, Stegeman CA, J Am Soc Nephrol 2005 16 1 195 200 15563558 (Pubitemid 43073173)
8. The pathophysiology of cardiac surgery-associated acute kidney injury (CSA-AKI). Bellomo R, Auriemma S, Fabbri A, D'Onofrio A, Katz N, McCullough PA, Ricci Z, Shaw A, Ronco C, Int J Artif Organs 2008 31 2 166 178 18311733 (Pubitemid 351425014)
9. Acute kidney injury associated with cardiac surgery. Rosner MH, Okusa MD, Clin J Am Soc Nephrol 2006 1 1 19 32 17699187
10. Pharmacological therapies for the prevention of acute kidney injury following cardiac surgery: a systematic review. Patel NN, Rogers CA, Angelini GD, Murphy GJ, Heart Fail Rev 2011 16 6 553 567 10.1007/s10741-011-9235-5 21400231
11. Preventing acute kidney injury after cardiac surgery. Coleman MD, Shaefi S, Sladen RN, Curr Opin Anaesthesiol 2011 24 1 70 76 10.1097/ACO. 0b013e3283422ebc 21157303
12. Erythropoietin (EPO) in acute kidney injury. Moore E, Bellomo R, Ann Intensive Care 2011 1 1 3 10.1186/2110-5820-1-3 21906325
13. Erythropoietin protects the kidney against the injury and dysfunction caused by ischemia-reperfusion. Sharples EJ, Patel N, Brown P, Stewart K, Mota-Philipe H, Sheaff M, Kieswich J, Allen D, Harwood S, Raftery M, et al. J Am Soc Nephrol 2004 15 8 2115 2124 10.1097/01.ASN.0000135059.67385.5D 15284297 (Pubitemid 39031350)
14. Erythropoietin decreases renal fibrosis in mice with ureteral obstruction: role of inhibiting TGF-beta-induced epithelial-to-mesenchymal transition. Park SH, Choi MJ, Song IK, Choi SY, Nam JO, Kim CD, Lee BH, Park RW, Park KM, Kim YJ, et al. J Am Soc Nephrol 2007 18 5 1497 1507 10.1681/ASN.2005080866 17389738 (Pubitemid 46717516)
15. Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Salahudeen AK, Haider N, Jenkins J, Joshi M, Patel H, Huang H, Yang M, Zhe H, Am J Physiol Renal Physiol 2008 294 6 1354 F1365 10.1152/ajprenal.00131.2008 18385271
16. Erythropoietin Ameliorates Renal Ischemia and Reperfusion Injury via Inhibiting Tubulointerstitial Inflammation. Hu L, Yang C, Zhao T, Xu M, Tang Q, Yang B, Rong R, Zhu T, J Surg Res 2012 176 1 260 266 10.1016/j.jss.2011.06.035 21816412
17. Antioxidative effects of erythropoietin. Katavetin P, Tungsanga K, Eiam-Ong S, Nangaku M, Kidney Int Suppl 2007 107 10 S15 17943138
18. Erythropoietin and renoprotection. Bahlmann FH, Fliser D, Curr Opin Nephrol Hypertens 2009 18 1 15 20 10.1097/MNH.0b013e32831a9dde 19077684
19. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. Drueke TB, Locatelli F, Clyne N, Eckardt KU, Macdougall IC, Tsakiris D, Burger HU, Scherhag A, N Engl J Med 2006 355 20 2071 2084 10.1056/NEJMoa062276 17108342 (Pubitemid 44749316)
20. Correction of anemia with epoetin alfa in chronic kidney disease. Singh AK, Szczech L, Tang KL, Barnhart H, Sapp S, Wolfson M, Reddan D, N Engl J Med 2006 355 20 2085 2098 10.1056/NEJMoa065485 17108343 (Pubitemid 44749317)
21. Reversal of anemia by erythropoietin therapy retards the progression of chronic renal failure, especially in nondiabetic patients. Kuriyama S, Tomonari H, Yoshida H, Hashimoto T, Kawaguchi Y, Sakai O, Nephron 1997 77 2 176 185 10.1159/000190270 9346384 (Pubitemid 27440408)
22. Treating anemia early in renal failure patients slows the decline of renal function: a randomized controlled trial. Gouva C, Nikolopoulos P, Ioannidis JP, Siamopoulos KC, Kidney Int 2004 66 2 753 760 10.1111/j.1523-1755. 2004.00797.x 15253730 (Pubitemid 38982019)
23. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Crit Care 2004 8 4 204 R212 10.1186/cc2872 15312219
24. Defining and classifying acute renal failure: from advocacy to consensus and validation of the RIFLE criteria. Bellomo R, Kellum JA, Ronco C, Intensive Care Med 2007 33 3 409 413 10.1007/s00134-006-0478-x 17165018 (Pubitemid 46333828)
25. Defining acute renal failure: physiological principles. Bellomo R, Kellum JA, Ronco C, Intensive Care Med 2004 30 1 33 37 10.1007/s00134-003-2078-3 14618231 (Pubitemid 38147105)
26. Diagnosis of acute kidney injury: from classic parameters to new biomarkers. Bonventre JV, Contrib Nephrol 2007 156 213 219 17464130
27. Biomarkers of kidney injury. Urbschat A, Obermuller N, Haferkamp A, Biomarkers 2011 16 Suppl 1 22 S30 21707441
28. Biomarkers for the diagnosis and risk stratification of acute kidney injury: a systematic review. Coca SG, Yalavarthy R, Concato J, Parikh CR, Kidney Int 2008 73 9 1008 1016 10.1038/sj.ki.5002729 18094679 (Pubitemid 351543898)
29. How to use biomarkers efficiently in acute kidney injury. Lameire NH, Vanholder RC, Van Biesen WA, Kidney Int 2011 79 10 1047 1050 10.1038/ki.2011.21 21527944
30. Urinary and serum biomarkers for the diagnosis of acute kidney injury: an in-depth review of the literature. Vanmassenhove J, Vanholder R, Nagler E, Van Biesen W, Nephrol Dial Transplant 2013 28 2 254 273 10.1093/ndt/gfs380 23115326
31. The outcome of neutrophil gelatinase-associated lipocalin-positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. Haase M, Devarajan P, Haase-Fielitz A, Bellomo R, Cruz DN, Wagener G, Krawczeski CD, Koyner JL, Murray P, Zappitelli M, et al. J Am Coll Cardiol 2011 57 17 1752 1761 10.1016/j.jacc.2010.11.051 21511111
32. Prevention and treatment of acute kidney injury in patients undergoing cardiac surgery: a systematic review. Park M, Coca SG, Nigwekar SU, Garg AX, Garwood S, Parikh CR, Am J Nephrol 2010 31 5 408 418 10.1159/000296277 20375494
33. Identification of neutrophil gelatinase-associated lipocalin as a novel early urinary biomarker for ischemic renal injury. Mishra J, Ma Q, Prada A, Mitsnefes M, Zahedi K, Yang J, Barasch J, Devarajan P, J Am Soc Nephrol 2003 14 10 2534 2543 10.1097/01.ASN.0000088027.54400.C6 14514731 (Pubitemid 37169339)
34. Review: neutrophil gelatinase-associated lipocalin: a troponin-like biomarker for human acute kidney injury. Devarajan P, Nephrology (Carlton) 2010 15 4 419 428 10.1111/j.1440-1797.2010.01317.x
35. Neutrophil gelatinase-associated lipocalin as a biomarker of acute kidney injury-where do we stand today? Schmidt-Ott KM, Nephrol Dial Transplant 2011 26 3 762 764 10.1093/ndt/gfr006 21310736
36. Neutrophil gelatinase-associated lipocalin: a novel early urinary biomarker for cisplatin nephrotoxicity. Mishra J, Mori K, Ma Q, Kelly C, Barasch J, Devarajan P, Am J Nephrol 2004 24 3 307 315 10.1159/000078452 15148457 (Pubitemid 39070114)
37. Urinary neutrophil gelatinase-associated lipocalin levels reflect damage to glomeruli, proximal tubules, and distal nephrons. Kuwabara T, Mori K, Mukoyama M, Kasahara M, Yokoi H, Saito Y, Yoshioka T, Ogawa Y, Imamaki H, Kusakabe T, et al. Kidney Int 2009 75 3 285 294 10.1038/ki.2008.499 19148153
38. Neutrophil gelatinase-associated lipocalin (NGAL) as a biomarker for acute renal injury after cardiac surgery. Mishra J, Dent C, Tarabishi R, Mitsnefes MM, Ma Q, Kelly C, Ruff SM, Zahedi K, Shao M, Bean J, et al. Lancet 2005 365 9466 1231 1238 10.1016/S0140-6736(05)74811-X 15811456 (Pubitemid 40469655)
39. Urinary neutrophil gelatinase-associated lipocalin and acute kidney injury after cardiac surgery. Wagener G, Gubitosa G, Wang S, Borregaard N, Kim M, Lee HT, Am J Kidney Dis 2008 52 3 425 433 10.1053/j.ajkd.2008.05.018 18649981
40. EPO: renoprotection beyond anemia correction. Fliser D, Bahlmann FH, Haller H, Pediatr Nephrol 2006 21 12 1785 1789 10.1007/s00467-006-0284-2 16957890 (Pubitemid 44741154)
41. Prevention of acute kidney injury by erythropoietin in patients undergoing coronary artery bypass grafting: a pilot study. Song YR, Lee T, You SJ, Chin HJ, Chae DW, Lim C, Park KH, Han S, Kim JH, Na KY, Am J Nephrol 2009 30 3 253 260 10.1159/000223229 19494484
42. Acute renal dysfunction after cardiac surgery with cardiopulmonary bypass is associated with plasmatic IL6 increase. Gueret G, Lion F, Guriec N, Arvieux J, Dovergne A, Guennegan C, Bezon E, Baron R, Carre JL, Arvieux C, Cytokine 2009 45 2 92 98 10.1016/j.cyto.2008.11.001
43. Recombinant human erythropoietin pretreatment attenuates heart ischemia-reperfusion injury in rats by suppressing the systemic inflammatory response. Shen Y, Wang Y, Li D, Wang C, Xu B, Dong G, Huang H, Jing H, Transplant Proc 2010 42 5 1595 1597 10.1016/j.transproceed.2009.11.050 20620481
44. Epoetin treatment improves red blood cell and plasma antioxidant capacity in hemodialysis patients. Mimic-Oka J, Simic T, Djukanovic L, Ren Fail 2002 24 1 77 87 10.1081/JDI-120002663 11921701 (Pubitemid 34229601)
45. Pharmacokinetics and erythropoietic response to human recombinant erythropoietin in healthy men. Flaharty KK, Caro J, Erslev A, Whalen JJ, Morris EM, Bjornsson TD, Vlasses PH, Clin Pharmacol Ther 1990 47 5 557 564 10.1038/clpt.1990.76 (Pubitemid 20190094)
46. Early intervention with erythropoietin does not affect the outcome of acute kidney injury (the EARLYARF trial). Endre ZH, Walker RJ, Pickering JW, Shaw GM, Frampton CM, Henderson SJ, Hutchison R, Mehrtens JE, Robinson JM, Schollum JB, et al. Kidney Int 2010 77 11 1020 1030 10.1038/ki.2010.25 20164823
47. Epoetin administrated after cardiac surgery: effects on renal function and inflammation in a randomized controlled study. de Seigneux S, Ponte B, Weiss L, Pugin J, Romand JA, Martin PY, Saudan P, BMC Nephrol 2012 13 1 132 10.1186/1471-2369-13-132 23033926
48. Acute renal failure after cardiac surgery: evaluation of the RIFLE classification. Kuitunen A, Vento A, Suojaranta-Ylinen R, Pettila V, Ann Thorac Surg 2006 81 2 542 546 10.1016/j.athoracsur.2005.07.047 16427848 (Pubitemid 43120552)
49. Costs and outcomes of acute kidney injury (AKI) following cardiac surgery. Dasta JF, Kane-Gill SL, Durtschi AJ, Pathak DS, Kellum JA, Nephrol Dial Transplant 2008 23 6 1970 1974 10.1093/ndt/gfm908 18178605 (Pubitemid 351768157)
50. Risk of poor outcomes with novel and traditional biomarkers at clinical AKI diagnosis. Hall IE, Coca SG, Perazella MA, Eko UU, Luciano RL, Peter PR, Han WK, Parikh CR, Clin J Am Soc Nephrol 2011 6 12 2740 2749 10.2215/CJN.04960511 22034509